"Our Phase 1 trials continue to provide valuable insight into the durability and unprecedented effects of SB-728-T treatment on immune system health in HIV-infected individuals," said Geoff Nichol, M.B., Ch.B ., Sangamo's executive vice president of research and development. "In addition we are making good progress in two Phase 2 clinical trials designed to maximize the engraftment of SB-728-T. We expect to present preliminary data in the first half of 2013 and a full data set in the second half of next year. The ground-breaking clinical data that we and our collaborators are generating continues to validate this treatment as a promising approach to provide a 'functional cure' for HIV/AIDS."
Abst.#H533: "Preferential expansion of transitional (T TM) and Central Memory(T CM) CD4 T-cells following adoptive transfer of ZFN CCR5 Modified Autologous CD4 T-cells." Monday, September 10, 2012: Oral session 073 (H) New Antiretroviral Therapy: Bench to Bedside.
Abst.#H-1581: "Digital droplet PCR (DD) qPCR allows quantiation of HIV proviral DNA in aviremic HIV+ subjects on HAART treated with ZFN CCR5 modified autologous CD4 T-cells (SB-728-T)." Tuesday, September 11, 2012, Poster Session 180 (H) HIV-I Resistance, Tropism and Novel Laboratory MethodsThe presentation will describe a new highly sensitive method developed by Sangamo scientists that enables accurate quantification of very low copy numbers of HIV DNA genomes, which may be a useful tool for evaluating interventions targeting the HIV reservoir, particularly Sangamo's approach to a 'functional cure' for the disease. For a more complete description of the technique click here About SB-728-T Sangamo's drug, SB-728-T, is generated by ZFN-mediated modification of the gene encoding the CCR5 receptor in a patient's own T-cells. ZFN modification disrupts the expression of this key co-receptor for HIV entry and renders cells resistant to HIV infection. The approach is based on the observation that a naturally occurring mutation in the CCR5 gene, CCR5 delta-32, provides protection from HIV infection. Individuals in whom both copies of the CCR5 gene carry the delta-32 mutation are generally not susceptible to the most common strain of HIV. The non-employee authors of these abstracts have no financial relationship with Sangamo.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts